Michael D. Clayman

1.5k total citations
39 papers, 1.2k citations indexed

About

Michael D. Clayman is a scholar working on Nephrology, Radiology, Nuclear Medicine and Imaging and Pharmacology. According to data from OpenAlex, Michael D. Clayman has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Nephrology, 14 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Pharmacology. Recurrent topics in Michael D. Clayman's work include Renal Diseases and Glomerulopathies (14 papers), Nephrotoxicity and Medicinal Plants (10 papers) and Osteoarthritis Treatment and Mechanisms (4 papers). Michael D. Clayman is often cited by papers focused on Renal Diseases and Glomerulopathies (14 papers), Nephrotoxicity and Medicinal Plants (10 papers) and Osteoarthritis Treatment and Mechanisms (4 papers). Michael D. Clayman collaborates with scholars based in United States, Canada and Australia. Michael D. Clayman's co-authors include Eric G. Neilson, E McCafferty, Richard A. Mann, David J. Miner, Hiroshi Shiraga, Min Wei, William J. VanDusen, Joseph R. Sherbotie, John W. Foreman and Craig T. Przysiecki and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Michael D. Clayman

39 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael D. Clayman United States 19 362 350 229 229 212 39 1.2k
R. Graham United Kingdom 15 126 0.3× 266 0.8× 454 2.0× 263 1.1× 237 1.1× 30 1.8k
Benjamin C. Sturgill United States 28 640 1.8× 327 0.9× 402 1.8× 613 2.7× 156 0.7× 57 2.1k
Philip de Groot Netherlands 24 88 0.2× 517 1.5× 269 1.2× 150 0.7× 163 0.8× 42 1.5k
P Druet France 25 332 0.9× 194 0.6× 269 1.2× 116 0.5× 288 1.4× 99 2.0k
Anthony J. Janckila United States 29 141 0.4× 279 0.8× 1.3k 5.6× 204 0.9× 161 0.8× 81 2.5k
Satoshi Kokubo Japan 19 223 0.6× 171 0.5× 339 1.5× 84 0.4× 33 0.2× 31 1.1k
Alexander Duncan United Kingdom 16 127 0.4× 266 0.8× 378 1.7× 84 0.4× 140 0.7× 25 1.7k
Dagmar‐Christiane Fischer Germany 24 375 1.0× 188 0.5× 494 2.2× 150 0.7× 63 0.3× 77 1.7k
Ah‐Kau Ng United States 17 114 0.3× 232 0.7× 203 0.9× 36 0.2× 153 0.7× 27 1.1k
E. W. Rauterberg Germany 14 232 0.6× 56 0.2× 291 1.3× 82 0.4× 106 0.5× 48 1.2k

Countries citing papers authored by Michael D. Clayman

Since Specialization
Citations

This map shows the geographic impact of Michael D. Clayman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Clayman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Clayman more than expected).

Fields of papers citing papers by Michael D. Clayman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Clayman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Clayman. The network helps show where Michael D. Clayman may publish in the future.

Co-authorship network of co-authors of Michael D. Clayman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Clayman. A scholar is included among the top collaborators of Michael D. Clayman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Clayman. Michael D. Clayman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2015). An Intra-Articular, Extended-Release Formulation of Triamcinolone Acetonide Prolongs and Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee. Journal of Bone and Joint Surgery. 97(11). 877–888. 98 indexed citations
4.
Bodick, N., Joelle Lufkin, Anjali S. Kumar, et al.. (2014). Safety and efficacy of FX006 in patients with osteoarthritis of the knee. Osteoarthritis and Cartilage. 22. S376–S377. 2 indexed citations
5.
Bodick, N., et al.. (2013). FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis. Osteoarthritis and Cartilage. 21. S144–S145. 14 indexed citations
6.
Kelly, Carolyn, Michael D. Clayman, William H. Hines, & Eric G. Neilson. (2007). Therapeutic Immune Regulation in Experimental Interstitial Nephritis with Suppressor T Cells and their Soluble Factors. Novartis Foundation symposium. 129. 73–87. 1 indexed citations
7.
Rudy, David W., et al.. (1993). Acyclovir Neurotoxicity and Nephrotoxicity-The Role for Hemodialysis. The American Journal of the Medical Sciences. 305(1). 36–39. 41 indexed citations
8.
Bang, Nils U. & Michael D. Clayman. (1992). Antithrombotic agents from salivary glands of hematophagous animals. Trends in Cardiovascular Medicine. 2(5). 183–188. 3 indexed citations
9.
Bang, Nils U., Olaf G. Wilhelm, & Michael D. Clayman. (1992). Coronary Thrombolysis and Reperfusion - Literature Review and Future Projections. Seminars in Interventional Radiology. 9(3). 195–207. 1 indexed citations
10.
Shiraga, Hiroshi, Min Wei, William J. VanDusen, et al.. (1992). Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.. Proceedings of the National Academy of Sciences. 89(1). 426–430. 353 indexed citations
11.
Neilson, Eric G., C J Kelly, William H. Hines, et al.. (1991). Molecular characterization of a major nephritogenic domain in the autoantigen of anti-tubular basement membrane disease.. Proceedings of the National Academy of Sciences. 88(5). 2006–2010. 28 indexed citations
12.
Bang, Nils U., Olaf G. Wilhelm, & Michael D. Clayman. (1989). After coronary thrombolysis and reperfusion, What next?. Journal of the American College of Cardiology. 14(4). 837–849. 28 indexed citations
13.
Bang, Nils U., Olaf G. Wilhelm, & Michael D. Clayman. (1989). Thrombolytic Therapy in Acute Myocardial Infarction. The Annual Review of Pharmacology and Toxicology. 29(1). 323–341. 6 indexed citations
14.
Mann, Richard A., C J Kelly, William H. Hines, et al.. (1987). Effector T cell differentiation in experimental interstitial nephritis. I. The development and modulation of effector lymphocyte maturation by I-J+ regulatory T cells.. The Journal of Immunology. 138(12). 4200–4208. 25 indexed citations
15.
Clayman, Michael D., A Martínez-Hernández, Robert Alper, et al.. (1985). Isolation and characterization of the nephritogenic antigen producing anti-tubular basement membrane disease.. The Journal of Experimental Medicine. 161(2). 290–305. 58 indexed citations
16.
17.
18.
Neilson, Eric G., E McCafferty, S M Phillips, Michael D. Clayman, & C J Kelly. (1984). Antiidiotypic immunity in interstitial nephritis. II. Rats developing anti-tubular basement membrane disease fail to make an antiidiotypic regulatory response: the modulatory role of an RT7.1+, OX8- suppressor T cell mechanism.. The Journal of Experimental Medicine. 159(4). 1009–1026. 30 indexed citations
19.
Nicola, Alejandro F. De, Michael D. Clayman, & Rose M. Johnstone. (1968). Hormonal Control of Ascorbic Acid Transport in Rat Adrenal Glands1. Endocrinology. 82(3). 436–446. 21 indexed citations
20.
Nicola, Alejandro F. De, Michael D. Clayman, & Rose M. Johnstone. (1968). In vitro Uptake of ascorbic acid-1-14C by adrenal glands of different species of animals. General and Comparative Endocrinology. 11(2). 332–337. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Graham Breakdown of academic impact, for papers by Benjamin C. Sturgill Breakdown of academic impact, for papers by Philip de Groot Breakdown of academic impact, for papers by P Druet Breakdown of academic impact, for papers by Anthony J. Janckila Breakdown of academic impact, for papers by Satoshi Kokubo Breakdown of academic impact, for papers by Alexander Duncan Breakdown of academic impact, for papers by Dagmar‐Christiane Fischer Breakdown of academic impact, for papers by Ah‐Kau Ng Breakdown of academic impact, for papers by E. W. Rauterberg
Rankless by CCL
2026